{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:33:56Z","timestamp":1785162836264,"version":"3.55.0"},"reference-count":94,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Next-generation vaccines are being developed to elicit durable and cross-protective immune responses against diverse pathogens, particularly those targeting the respiratory and enteric systems. By strategically engaging T cell-centric antigen design, mucosal immune engagement, and induction of trained innate immunity, these innovative platforms are expected to reshape the paradigm of immunoprophylaxis and to offer promising avenues for enhanced protection against complex infectious diseases. Conventional antibody-based vaccines, though effective against many infections, often lack the capacity to induce durable or cross-protective immunity at mucosal surfaces. Advances in antigen design, delivery platforms, and adjuvant technologies now facilitate precise activation of tissue-resident memory T cells and enhancement of mucosal secretory IgA responses, thereby achieving sterilizing immunity at barrier surfaces while reinforcing systemic immune protection. Advanced delivery platforms, including lipid nanoparticles, viral vectors, and nano or liposomal carriers, further refine antigen presentation, enhancing stability, targeting, and overall immunogenicity. Concurrently, progress in understanding trained innate immunity highlights opportunities to induce broad, non-antigen-specific protection through epigenetic and metabolic reprogramming of innate cells. The integration of these adaptive and innate mechanisms may enhance early pathogen control, limits transmission, and strengthens defense against variant and antimicrobial-resistant pathogens across diverse populations. However, translating these immunological insights into safe, scalable, and globally accessible vaccines remains a major challenge. This review explores the emerging conceptual framework of next-generation vaccines that demonstrate partial integration of these axes in preclinical models, though human translation and functional synergy require Phase II validation. It highlights progress toward next-generation vaccines leveraging integrated adaptive and innate immune reprogramming for superior protection against respiratory and enteric pathogens.<\/jats:p>","DOI":"10.3390\/vaccines14050462","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:02:27Z","timestamp":1779375747000},"page":"462","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Next-Generation Vaccines Leveraging T Cell-Centric Design, Mucosal Immunity, and Trained Innate Immunity for Respiratory and Enteric Pathogens"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7424-9237","authenticated-orcid":false,"given":"Md. Abdus","family":"Salam","sequence":"first","affiliation":[{"name":"Faculty of Biotechnology & Biomedical Engineering, Rajshahi Medical University, Rajshahi 6100, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6086-5159","authenticated-orcid":false,"given":"Md. Yusuf","family":"Al-Amin","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, USA"},{"name":"Purdue University Interdisciplinary Life Sciences Graduate Program, Purdue University, West Lafayette, IN 47907, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7072-3226","authenticated-orcid":false,"given":"Kasireddy","family":"Sudarshan","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Purdue University College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Reyes","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Purdue University, West Lafayette, IN 47907, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Department of Agricultural and Biological Engineering, Purdue University, West Lafayette, IN 47907, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","year":"2020","journal-title":"Nat. Mater."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chen, K., Hu, J., Li, J., Wu, G., Tie, X., Wu, H., Li, H., Li, J., and Zhang, Y. (2025). Harnessing cellular immunity for next-generation vaccines against respiratory viruses: Mechanisms, platforms, and optimization strategies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1618406"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s43556-025-00301-7","article-title":"Mucosal immunity and vaccination strategies: Current insights and future perspectives","volume":"6","author":"Zhang","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Eslami, M., Fadaee Dowlat, B., Yaghmayee, S., Habibian, A., Keshavarzi, S., Oksenych, V., and Naderian, R. (2025). Next-generation vaccine platforms: Integrating synthetic biology, nanotechnology, and systems immunology for improved immunogenicity. Vaccines, 13.","DOI":"10.3390\/vaccines13060588"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yuan, F., and Bluth, M.H. (2025). Novel strategies for developing next-generation vaccines to combat infectious viral diseases. Vaccines, 13.","DOI":"10.3390\/vaccines13090979"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12985-025-02880-x","article-title":"Revolutionizing immunization: A comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol. J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chentoufi, A.A., Ulmer, J.B., and BenMohamed, L. (2025). Antigen delivery platforms for next-generation coronavirus vaccines. Vaccines, 13.","DOI":"10.3390\/vaccines13010030"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-024-02043-4","article-title":"Mucosal immune response in biology, disease prevention and treatment","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41541-025-01280-0","article-title":"Advances and prospects of respiratory mucosal vaccines: Mechanisms, technologies, and clinical applications","volume":"10","author":"Li","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wang, H., Xie, S., Huang, S., Huang, X., Zhang, Y., Wu, J., Fan, X.-Y., and Hu, Z. (2026). Mucosal Adenovirus-Vectored Rv2299c Vaccine Protects Against Tuberculosis by Inducing Trained Immunity in Dendritic Cells and Polyfunctional T Cells. Vaccines, 14.","DOI":"10.3390\/vaccines14010055"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s44155-026-00364-z","article-title":"Building equitable and sustainable vaccine ecosystems in Africa to achieve health sovereignty and universal immunization by 2040","volume":"6","author":"Okesanya","year":"2026","journal-title":"Discov. Soc. Sci. Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"116939","DOI":"10.5501\/wjv.v15.i1.116939","article-title":"Next-generation mucosal vaccines for respiratory viruses: Immunological correlates, platform design and clinical translation","volume":"15","author":"Younas","year":"2026","journal-title":"World J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1016\/j.cell.2024.07.021","article-title":"Transforming vaccinology","volume":"187","author":"Rappuoli","year":"2024","journal-title":"Cell"},{"key":"ref_16","first-page":"e100608","article-title":"A Comprehensive Review of Vaccine Development: From Traditional Platforms to Messenger RNA (mRNA) Technologies","volume":"18","author":"Pawar","year":"2026","journal-title":"Cureus"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chen, H., Gu, Y., Song, L., and Si, L. (2025). Next-generation vaccines against bacterial pathogens: mRNA and beyond. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1709794"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1038\/s41467-025-60726-0","article-title":"Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: An open-label, multi-arm phase 1 clinical trial","volume":"16","author":"Jeyanathan","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1003203","DOI":"10.37349\/ei.2025.1003203","article-title":"Advancements in viral vaccine development: From traditional to modern approaches","volume":"5","author":"Kumar","year":"2025","journal-title":"Explor. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Babawale, P.I., and Guerrero-Plata, A. (2024). Respiratory viral coinfections: Insights into epidemiology, immune response, pathology, and clinical outcomes. Pathogens, 13.","DOI":"10.3390\/pathogens13040316"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2365","DOI":"10.1002\/rmv.2365","article-title":"Respiratory viral co-infections in patients with COVID-19 and associated outcomes: A systematic review and meta-analysis","volume":"33","author":"Krumbein","year":"2023","journal-title":"Rev. Med. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wei, Z., Zhang, S., Wang, X., Xue, Y., Dang, S., and Zhai, J. (2025). Technological breakthroughs and advancements in the application of mRNA vaccines: A comprehensive exploration and future prospects. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1524317"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.chom.2023.12.003","article-title":"Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant","volume":"32","author":"Nesamari","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s10238-025-01772-2","article-title":"Predicting SARS-CoV-2-specific CD4+ and CD8+ T-cell responses elicited by inactivated vaccines in healthy adults using machine learning models","volume":"25","author":"Ning","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, M., Ali, S.L., Tian, Y., Abduldayeva, A., Zhou, S., An, Y., Li, Y., Ni, R., Zhang, L., and Liu, Y. (2025). EP9158H: An immunoinformatics-designed mRNA vaccine encoding multi-epitope antigens and dual TLR agonists for tuberculosis prevention. Bioengineering, 12.","DOI":"10.3390\/bioengineering12121378"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rawat, S.S., Keshri, A.K., Kaur, R., and Prasad, A. (2023). Immunoinformatics approaches for vaccine design: A fast and secure strategy for successful vaccine development. Vaccines, 11.","DOI":"10.3390\/vaccines11020221"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Patricio, O., Manju, K., Victor, F., Salas-Burgos, A., Gonzalez-Galarza, F.F., McCabe, A., Jones, A.R., Middleton, D., and Kobe, B. (2021). A proteome-wide immunoinformatics tool to accelerate T-cell epitope discovery and vaccine design in the context of emerging infectious diseases: An ethnicity-oriented approach. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.598778"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wang, C.Y., Peng, W.-J., Kuo, B.-S., Ho, Y.-H., Wang, M.-S., Yang, Y.-T., Chang, P.-Y., Shen, Y.-H., and Hwang, K.-P. (2023). Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1010870"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Jalili, S., Hosn, R.R., Ko, W.C., Afshari, K., Dhinakaran, A.K., Chaudhary, N., Maiorino, L., Haddadi, N., Nathan, A., and Getz, M.A. (2026). Leveraging tissue-resident memory T cells for non-invasive immune monitoring via microneedle skin patches. Nat. Biomed. Eng.","DOI":"10.1038\/s41551-026-01617-7"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00997-25","DOI":"10.1128\/jvi.00997-25","article-title":"Broad-spectrum vaccines against various and evolving viruses: From antigen design to nanoparticle delivery","volume":"99","author":"Cao","year":"2025","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41423-024-01140-2","article-title":"Mucosal T-cell responses to chronic viral infections: Implications for vaccine design","volume":"21","author":"Dimonte","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tang, J., Amin, M.A., and Campian, J.L. (2025). Past, present, and future of viral vector vaccine platforms: A comprehensive review. Vaccines, 13.","DOI":"10.3390\/vaccines13050524"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2501844","DOI":"10.1080\/21645515.2025.2501844","article-title":"T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine","volume":"21","author":"Haltaufderhyde","year":"2025","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15235","DOI":"10.2147\/IJN.S557690","article-title":"Nanomaterial-enhanced immunotherapy: Advancing T-cell-based treatments for bladder cancer","volume":"20","author":"Chen","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Swayam, P., Dhanushkodi, N.R., Latifa, Z., Coimbra, I.I., Afshana, Q., Gregoire, C.P., Tifrea, D.F., Suzer, B., Shaik, A.M., and Chilukuri, A. (2024). Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1328905"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1038\/s41598-022-21207-2","article-title":"A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron","volume":"12","author":"Wallace","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.jid.2023.03.1672","article-title":"Microneedle-mediated immunization promotes lung CD8+ T-cell immunity","volume":"143","author":"Yu","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Tang, X., Zhang, W., and Zhang, Z. (2025). Developing T cell epitope-based vaccines against infection: Challenging but worthwhile. Vaccines, 13.","DOI":"10.3390\/vaccines13020135"},{"key":"ref_40","first-page":"20499361251411188","article-title":"Advancing peptide-based vaccines against viral pathogens: A narrative review","volume":"13","author":"Jahantigh","year":"2026","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sun, M., Lu, F., Yu, D., Wang, Y., Chen, P., and Liu, S. (2024). Respiratory diseases and gut microbiota: Relevance, pathogenesis, and treatment. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1358597"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hua, S.Y., and Hasnain, S.Z. (2022). Mucus and mucins: The underappreciated host defence system. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.856962"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pietrzak, B., Tomela, K., Olejnik-Schmidt, A., Mackiewicz, A., and Schmidt, M. (2020). Secretory IgA in intestinal mucosal secretions as an adaptive barrier against microbial cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239254"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Yangbao, L., Yuming, Z., and Jun, S. (2022). An overview of tissue-resident memory T cells in the intestine: From physiological functions to pathological mechanisms. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.912393"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Grondin, J.A., Kwon, Y.H., Far, P.M., Haq, S., and Khan, W.I. (2020). Mucins in intestinal mucosal defense and inflammation: Learning from clinical and experimental studies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.02054"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: Function, regulation and therapeutic potential","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103809","DOI":"10.1016\/j.sjbs.2023.103809","article-title":"Live attenuated influenza vaccine induces broadly cross-reactive mucosal antibody responses to different influenza strains in tonsils","volume":"10","author":"Mahallawi","year":"2023","journal-title":"Saudi J. Biol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1086\/605035","article-title":"Oral rotavirus vaccines: How well will they work where they are needed most?","volume":"200","author":"Patel","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2368288","DOI":"10.1080\/21645515.2024.2368288","article-title":"Induction of protective immune responses at respiratory mucosal sites","volume":"20","author":"Park","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Alqahtani, S.A.M. (2024). Mucosal immunity in COVID-19: A comprehensive review. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1433452"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Yang, Y., Huang, L., Yuan, L., Huang, S., Zeng, Z., Cao, Y., Wei, X., Wang, X., and Shi, M. (2025). Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1573037"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Wang, J., Qin, S., Li, K., Yin, X., Sun, D., and Chang, J. (2025). Rotavirus reverse genetics systems and oral vaccine delivery vectors for mucosal vaccination. Microorganisms, 13.","DOI":"10.3390\/microorganisms13071579"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(25)00380-9","article-title":"Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: A Danish, nationwide, register-based, cohort study","volume":"25","author":"Hansen","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/imr.13088","article-title":"Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine","volume":"310","author":"Hendriks","year":"2022","journal-title":"Immunol. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.imlet.2019.10.013","article-title":"Mucosal vaccines: Strategies and challenges","volume":"217","author":"Li","year":"2020","journal-title":"Immunol. Lett."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Song, Y., Mehl, F., and Zeichner, S.L. (2024). Vaccine strategies to elicit mucosal immunity. Vaccines, 12.","DOI":"10.3390\/vaccines12020191"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.hlife.2023.12.005","article-title":"Mucosal vaccine development for respiratory viral infections","volume":"2","author":"Lin","year":"2024","journal-title":"hLife"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Ram\u00f3n, S., Conejero, L., Netea, M.G., Sancho, D., Palomares, \u00d3., and Subiza, J.L. (2018). Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02936"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41581-022-00633-5","article-title":"Trained immunity\u2014Basic concepts and contributions to immunopathology","volume":"19","author":"Ochando","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.immuni.2022.04.007","article-title":"Immunity to enteric viruses","volume":"55","author":"Lockhart","year":"2022","journal-title":"Immunity"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Jurczak, M., and Druszczynska, M. (2025). Beyond tuberculosis: The surprising immunological benefits of the Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccine in infectious, auto-immune, and inflammatory diseases. Pathogens, 14.","DOI":"10.3390\/pathogens14020196"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.chom.2023.05.004","article-title":"The role of trained immunity in COVID-19: Lessons for the next pandemic","volume":"31","author":"Netea","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Dagenais, A., Villalba-Guerrero, C., and Olivier, M. (2023). Trained immunity: A \u201cnew\u201d weapon in the fight against infectious diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1147476"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"109930","DOI":"10.1016\/j.clim.2024.109930","article-title":"Trained immunity-inducing vaccines: Harnessing innate memory for vaccine design and delivery","volume":"261","author":"Baydemir","year":"2024","journal-title":"Clin. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Marzouk, E., and Alajaji, A.I. (2025). Preventive immunology for livestock and zoonotic infectious diseases in the One Health era: From mechanistic insights to innovative interventions. Vet. Sci., 12.","DOI":"10.3390\/vetsci12101014"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e00472-24","DOI":"10.1128\/iai.00472-24","article-title":"Infection-induced trained immunity: A twist in paradigm of innate host defense and generation of immunological memory","volume":"93","author":"Bahl","year":"2025","journal-title":"Infect. Immun."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kim, H.G., Rincon, J.C., Efron, P.A., and Maile, R. (2025). DAMP-driven trained immunity: Metabolic and epigenetic reprogramming in critical illness and chronic inflammation. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1669054"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e1345","DOI":"10.1002\/cti2.1345","article-title":"Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections","volume":"10","author":"Elkashif","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"14557","DOI":"10.3389\/bjbs.2025.14557","article-title":"Systematic Review of Clinical Trials Using mRNA Vaccines for Infectious Diseases other than COVID-19","volume":"82","author":"Sofroniou","year":"2025","journal-title":"Br. J. Biomed. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-023-00654-6","article-title":"Mucosal vaccines for SARS-CoV-2: Scientific gaps and opportunities-workshop report","volume":"8","author":"Knisely","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Taranc\u00f3n, R., Dom\u00ednguez-Andr\u00e9s, J., Uranga, S., Ferreira, A.V., Groh, L.A., Domenech, M., Gonz\u00e1lez-Camacho, F., Riksen, N.P., Aguilo, N., and Yuste, J. (2020). New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008404"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ghattas, M., Dwivedi, G., Lavertu, M., and Alameh, M.G. (2021). Vaccine technologies and platforms for infectious diseases: Current progress, challenges, and opportunities. Vaccines, 9.","DOI":"10.3390\/vaccines9121490"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"24224","DOI":"10.1038\/s41598-025-06880-3","article-title":"Intranasal booster induces durable mucosal immunity against SARS-CoV-2 in mice","volume":"15","author":"Hill","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Carvalho, A.C.O., Trentini, M.M., Rodriguez, D., Marques-Neto, L.M., Silveira, P.H.S., Starobinas, N., Oliveira, S.C., de Cerqueira Leite, L.C., and Kanno, A.I. (2026). Broad innate immune activation enhances the protective efficacy of rBCG-LTAK63 against Mycobacterium tuberculosis. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1758476"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e104918","DOI":"10.7554\/eLife.104918","article-title":"Trained immunity in the lung","volume":"14","author":"Idiiatullina","year":"2025","journal-title":"eLife"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e09022","DOI":"10.1002\/advs.202509022","article-title":"Polysaccharide adjuvants as innate immune trainers: Bridging pattern recognition receptor activation and metabolic reprogramming for synthetic vaccine design","volume":"12","author":"Moon","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Chen, J., Wang, C., Chen, S., Cai, H., Wang, M., Chang, J., Cai, X., Yang, J., and Cao, P. (2025). Trained immunity modulators: A new frontier in immunoregulation and disease intervention. J. Adv. Res.","DOI":"10.1016\/j.jare.2025.09.029"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"0879","DOI":"10.34133\/research.0879","article-title":"Microneedle Technology for Overcoming Biological Barriers: Advancing Biomacromolecular Delivery and Therapeutic Applications in Major Diseases","volume":"12","author":"Ye","year":"2025","journal-title":"Research"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Nguyen, H.X. (2025). Beyond the needle: Innovative microneedle-based transdermal vaccination. Medicines, 12.","DOI":"10.3390\/medicines12010004"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Hassan, J., Haigh, C., Ahmed, T., Uddin, M.J., and Das, D.B. (2022). Potential of microneedle systems for COVID-19 vaccination: Current trends and challenges. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051066"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1016\/j.apsb.2024.08.026","article-title":"Respiratory delivered vaccines: Current status and perspectives in rational formulation design","volume":"14","author":"Wu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.preme.2025.100040","article-title":"Engineering mucosal immunity: Advanced vaccine platforms against respiratory pathogens","volume":"2","author":"Wang","year":"2025","journal-title":"Precis. Med. Eng."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41579-021-00535-6","article-title":"Transmissibility and transmission of respiratory viruses","volume":"19","author":"Leung","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","article-title":"Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management","volume":"26","author":"Chavda","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40121-024-01082-2","article-title":"Respiratory virus vaccines: Pathways to recommendations and enhanced coverage for at-risk populations","volume":"14","author":"Maggi","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Chen, J., Grow, S., Iturriza-G\u00f3mara, M., Hausdorff, W.P., Fix, A., and Kirkwood, C.D. (2022). The challenges and opportunities of next-generation rotavirus vaccines: Summary of an expert meeting with vaccine developers. Viruses, 14.","DOI":"10.3390\/v14112565"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.cmi.2018.06.023","article-title":"Update on vaccines for enteric pathogens","volume":"24","author":"Riddle","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2549585","DOI":"10.1080\/19490976.2025.2549585","article-title":"The emerging role of the gut microbiota in vaccination responses","volume":"17","author":"Decker","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Kuo, T.H., and Chen, Y.C. (2025). Biotechnology and the future of vaccines\u2014From novel routes and vectors to safety, efficacy, and global impact. Vaccines, 13.","DOI":"10.3390\/vaccines13101043"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"235","DOI":"10.7774\/cevr.2022.11.3.235","article-title":"Development of mucosal vaccine delivery: An overview on the mucosal vaccines and their adjuvants","volume":"11","author":"Anggraeni","year":"2022","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2563709","DOI":"10.1080\/19490976.2025.2563709","article-title":"Gut microbiota as a regulator of vaccine efficacy: Implications for personalized vaccination","volume":"17","author":"Lu","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"102234","DOI":"10.1016\/j.coi.2022.102234","article-title":"The next frontier in vaccine design: Blending immune correlates of protection into rational vaccine design","volume":"78","author":"Britto","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1093\/cid\/ciaf412","article-title":"Future goals and long-term vision of the Infectious Diseases Clinical Research Consortium\/Vaccine and Treatment Evaluation Unit Network","volume":"81","author":"Whitaker","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"425","DOI":"10.24171\/j.phrp.2025.0208","article-title":"Bridging innovation and policy: Comparative pathways of national vaccine development in low- and middle-income countries","volume":"16","author":"Marandi","year":"2025","journal-title":"Osong Public Health Res. Perspect."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/5\/462\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:23:27Z","timestamp":1779769407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/5\/462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":94,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["vaccines14050462"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14050462","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}